Aberrant anaplastic lymphoma kinase expression in high-grade pulmonary neuroendocrine carcinoma

Journal of Clinical Pathology

Volumn 66, Issue 8, 2013, Pages 705-707

  Nakamura, Harumi ^a   Tsuta, Koji ^a   Yoshida, Akihiko ^a   Shibata, Tatsuhiro ^b   Wakai, Susumu ^a   Asamura, Hisao ^a   Furuta, Koh ^a   Tsuda, Hitoshi ^a  

^a NATIONAL CANCER CENTER HOSPITAL   (Japan)

^b NATIONAL CANCER CENTER RESEARCH INSTITUTE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE;

ARTICLE; CANCER TISSUE; CARCINOID; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE EXPRESSION; GENE REARRANGEMENT; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; LARGE CELL CARCINOMA; LUNG CARCINOMA; LUNG SMALL CELL CANCER; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY NEUROENDOCRINE CARCINOMA; TISSUE MICROARRAY;

IMMUNOHISTOCHEMISTRY; LUNG; NEUROENDOCRINE TUMOURS;

CARCINOMA, NEUROENDOCRINE; HUMANS; LUNG NEOPLASMS; NEOPLASM GRADING; RECEPTOR PROTEIN-TYROSINE KINASES; TUMOR MARKERS, BIOLOGICAL;

EID: 84880626082     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-201329     Document Type: Article

References (13)

1. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-6.
2. Kwak EL, Bang KJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-703.
3. Mino-Kenudson M, Chirieac LR, Law K, et al. A novel, highly sensitive antibody allows for the routine detection of ALK-rearranged lung adenocarcinomas by standard immunohistochemistry. Clin Cancer Res 2010;16:1561-71.
4. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143-9.
5. Yoshida A, Tsuta K, Nakamura H, et al. Comprehensive histologic analysis of ALK-rearranged lung carcinomas. Am J Surg Pathol 2011;35:1226-34.
6. Travis WD, Brambilla E, Muller-Hemelink HK, et al. World Health Organization classification of tumors. Pathology and genetics of tumors of the lung, pleura, thymus and heart. Lyon: IARC Press, 2004.
7. Takeuchi K, Soda M, Togashi Y, et al. RET, ROS1 and ALK fusion in lung cancer. Nat Med 2012;18:378-81.
8. Iwahara T, Fujimoto J, Wen D, et al. Molecular characterization of ALK, a receptor tyrosine kinase expressed specifically in the nervous system. Oncogene 1997;14:439-49.
9. Yoshida A, Tsuta K, Nitta H, et al. Bright-field dual-colour chromogenic in situ hybridization for diagnosing echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase-positive lung adenocarcinomas. J Thorac Oncol 2011;6:1677-86.
10. Rimkunas VM, Crosby K, Hu Y, et al. Analysis of receptor tyrosine kinase ROS1 positive tumors in non-small cell lung cancer: Identification of a FIG-ROS1 fusion. Clin Cancer Res 2012;18:4449-57.
11. Nicholson SA, Beasley MB, Brambilla E, et al. Small cell lung carcinoma (SCLC): A clinicopathologic study of 100 cases with surgical specimens. Am J Surg Pathol 2002;26:1184-97.
12. Asamura H, Kameya T, Matsuno Y, et al. Neuroendocrine neoplasm of the lung: A prognostic spectrum. J Clin Oncol 2006;24:70-6.
13. Turner BM, Cagle PT, Sainz IM, et al. Napsin A, a new marker for lung adenocarcinoma, is complementary and more sensitive and specific than thyroid factor 1 in the differential diagnosis of primary pulmonary carcinoma: Evaluation of 1674 cases by tissue microarray. Arch Pathol Lab Med 2012;136:163-71.